Waters Introduces Ion Mobility-Enhanced Research Mass Spectrometer

Article

Waters Corporation introduced the Waters SYNAPT G2-Si Mass Spectrometer, which integrates a third dimension of resolution and separation power.

Waters Corporation introduced the Waters SYNAPT G2-Si Mass Spectrometer, which integrates a third dimension of resolution and separation power into a new suite of untargeted and targeted LC/MS/MS workflows. The system combines the power of Travelling Wave (T-Wave) Ion Mobility Separations with new data acquisition and informatics technologies, and collision cross section (CCS) measurements.

The mass spectrometer is the first MS system to elevate CCS alongside retention time and mass to charge ratio (m/z) as a robust, reliable identification parameter in library-based screening, according to a Waters press statement. The collision cross section of a molecule is an important distinguishing feature that is directly related to its chemical structure and three-dimensional conformation in the gas-phase. Like molecular mass, this additional orthogonal property of a molecule (through the use of high-efficiency T-wave ion mobility technology) gives scientists increased coverage and clarity for profiling mixtures or gaining additional measurements with which they can investigate chemical structures or better confirm a molecule's identity.

The system offers maximized time-of-flight (Tof) duty cycle and effective sensitivity, of up to 10x in MS/MS mode, for targeted discovery and quantitation. Improved LC/MS/MS efficiency includes a 40% improvement in the numbers of proteins identified from an E. coli sample and the identification of more than 2,000 proteins from a HeLa sample. A 2.5KHz solid-state laser combines with new software for improved spatial resolution (down to 15 microns) for cleaner mass spectral data and greater image throughput when performing experiments with MALDI imaging and T-wave ion mobility.

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content